Tandem Diabetes: Cheap at Roughly 1x Sales, but the Discount Is Not Yet Earned

Tandem Diabetes Care has spent the past month giving back a large slice of a year-long rally. The maker of automated insulin pumps has fallen about 27% over the past month to near $17, roughly 40% below its 52-week high of about $30, leaving the whole company worth about $1.2 billion. The market's explanation is easy to find: Tandem is still losing money, and the two fixes management is banking on — selling pumps through pharmacies on a pay-as-you-go basis and launching a new tubeless pump — are both unfinished.

It is a name that a top-performing small-cap value shop has been watching. In its second-quarter letter, the Keeley Small Cap Fund called Tandem the third-largest player in the global automated insulin pump market, with about $1 billion of revenue and a 500,000-device installed base, and framed the pharmacy pivot and the pending tubeless pump as the catalysts that could drive oversized growth.

The business is quietly improving

Start with the numbers that argue for the stock. In the quarter ended June 30, Tandem reported sales of $254.6 million, up about 6% from a year earlier. The net loss roughly halved, to $21.2 million from $52.4 million a year ago. Gross margin climbed to 57% from 52%, and adjusted EBITDA swung positive to $6.4 million. Pump shipments topped 33,000 worldwide, 22,000 of them in the United States.

So this is not the pattern where a falling valuation is merely mirroring a deteriorating company. The shares have moved down sharply while the underlying operations have been moving up. That alone buys a second look.

Why the discount is doing its job

But a resettled valuation is not the same thing as a bargain. Tandem ends the period worth near $1.2 billion against roughly $1.04 billion of trailing revenue — a price-to-sales ratio around 1.1x. That is cheap next to Insulet, the tubeless-pump leader, which trades near 3.2x sales and is profitable, and very cheap next to Dexcom's roughly 6.6x. The gap is the point, not a coincidence: the market is discounting Tandem because it does not yet make money and because its two recovery levers are unproven at scale.

The two unproven fixes

The first is the pharmacy shift. Tandem historically sold its pumps through medical-equipment distributors who billed insurers — a slow, restrictive route. The new "pay-as-you-go" pharmacy model lets a patient walk out with a pump under a monthly arrangement, removing the biggest upfront barrier for people considering a pump at all. In its first full quarter the pharmacy channel drove about 10% of U.S. sales, with roughly 45% of relevant formularies covered. Adoption that fast is encouraging, but it reshuffles when and how revenue shows up, and a slower-than-expected start to this transition is exactly what knocked the stock down after the first-quarter report. The scale is still modest: management reaffirmed about $1.08 billion of 2026 sales, at a gross margin near 56–57% and an adjusted EBITDA margin of 5–6%.

The second lever is the tubeless pump. Tandem has submitted a 510(k) application to the FDA for the tubeless Mobi and expects clearance in the second half of 2026. Its compact Mobi already makes up more than half of new-customer shipments, which is why the tubeless version matters: it is a direct challenge to Insulet's Omnipod, inside the category where a much larger, profitable rival already leads. Management itself describes the margin payoff as arriving more in 2027 than this year — an offensive launch into a competitor's stronghold, not a guaranteed quick win.

What separates a bargain from a trap

For a loss-making company growing in the mid-single digits, a cheap multiple is compensation for unresolved risk, not free money. That leaves the decision on a short, concrete clock. Two proof points over the next two to four quarters would tell the story: first, whether pharmacy-driven sales scale well past 10% of U.S. revenue while gross margin holds near 56–57% and the company moves closer to funding itself; second, whether the tubeless Mobi clears the FDA and launches without another supply-chain stumble — component supply has already been a drag this year. If the pharmacy model lifts growth above mid-single digits and margins hold, today's roughly 1x-sales price would look too cheap. If the transition keeps compressing near-term economics and growth stalls, "cheap" will have simply described the right price.

That is the honest read: the valuation has already reset, but the business has not yet proven it can monetize the pivot the discount is waiting on. This is a "too early" rather than a must-own — a turnaround with genuinely improving margins and a narrowing loss, held back by an unproven channel change and a product launch against a stronger rival, on a balance sheet that still cannot fully fund itself from operations. The next two to four quarters of pharmacy numbers and a tubeless approval are the evidence that will decide whether the discount was a mispricing or a fair warning.